Industry-Specific Risks in a Sponsor's Business Due Diligence of the Listing Applicant

The SFC’s 2024 thematic review of sponsor due diligence, published in December 2024, identified industry-specific risk assessment as the single largest deficiency in listing application work. Of the 30 cases reviewed, 22 (73.3%) contained at least one material failure to identify or verify risks unique to the applicant’s sector. This finding is not a compliance footnote — it directly triggers SFC enforcement under the Code of Conduct for Persons Licensed by or Registered with the SFC, paragraph 17.6, which requires sponsors to “conduct reasonable due diligence to satisfy themselves that the listing applicant’s business is suitable for listing.” The SFC has made clear that generic, checklist-based diligence across all sectors no longer meets the standard. For sponsors holding Type 6 (advising on corporate finance) and Type 6A (sponsor) licences, the implication is structural: every engagement must now begin with a sector-specific risk framework, not a standardised work programme. The HKEX’s Listing Decision LD143-2023, which rejected a listing application on grounds of inadequate due diligence into revenue recognition in a software-as-a-service business, provides the judicial precedent. This article examines the three highest-risk sectors in current Hong Kong IPO pipeline — healthcare/life sciences, technology/software, and financial services — and maps the specific due diligence protocols sponsors must deploy.

Healthcare and Life Sciences: Revenue Recognition and R&D Capitalisation

The healthcare sector accounted for 18.6% of all Main Board listing applications filed in H1 2025 (HKEX, Monthly Listing Statistics, June 2025). This concentration creates a compliance risk concentration for sponsors, as the sector presents two structural due diligence traps: revenue recognition for products under regulatory approval, and capitalisation of research and development expenditures under Hong Kong Financial Reporting Standards (HKFRS).

Revenue Recognition Under Conditional Approvals

A listing applicant in biopharmaceuticals or medical devices typically generates revenue from licensing agreements, milestone payments, or early-stage product sales before obtaining full regulatory approval from the National Medical Products Administration (NMPA) or the U.S. Food and Drug Administration (FDA). The SFC’s December 2024 review cited three cases where sponsors accepted revenue recognition under HKFRS 15 without verifying the contractual conditions precedent. The standard requires that revenue be recognised only when “it is highly probable that a significant reversal in the cumulative revenue recognised will not occur” (HKFRS 15, paragraph 56). For milestone payments tied to clinical trial phases, the probability threshold is rarely met until the trial results are published and accepted by the regulator.

The sponsor’s due diligence must include a contractual review of each material revenue stream against the five-step model in HKFRS 15, with specific attention to variable consideration constraints. A practical protocol: request the applicant’s revenue recognition policy for each product line, then independently verify the regulatory status of each product against NMPA or FDA public databases. The SFC expects the sponsor to document why each milestone payment meets the “highly probable” threshold, referencing specific clauses in the licensing agreement and the corresponding regulatory filing date. Failure to do so was the basis for the HKEX’s rejection in LD143-2023, where the exchange found the sponsor had not verified that the applicant’s revenue from pre-approval product sales was refundable under the supply agreement.

R&D Capitalisation Thresholds

Under HKFRS 38, development costs may be capitalised only when an entity can demonstrate technical feasibility, intention to complete, ability to use or sell the asset, generation of future economic benefits, availability of resources, and reliable measurement of expenditure (paragraphs 57-67). In the SFC’s review, 8 of the 22 deficient cases (36.3%) involved healthcare applicants that capitalised R&D costs without meeting these criteria. The most common failure: the applicant had not obtained a patent or regulatory filing that demonstrated technical feasibility at the balance sheet date.

Sponsors must require the applicant to provide a detailed R&D capitalisation memorandum for each material project, cross-referenced to patent applications, clinical trial registrations (ClinicalTrials.gov or the Chinese Clinical Trial Register), and NMPA acceptance letters. The sponsor’s compliance team should then reconcile the capitalised amounts to the supporting documents, with a tolerance threshold of no more than 5% variance per project. Where the applicant has capitalised costs for a project that has not yet entered Phase II clinical trials, the sponsor should treat this as a red flag requiring written justification from the applicant’s auditors and an independent technical expert’s opinion. The HKEX Listing Rule 11.06 requires the sponsor to “exercise reasonable skill and care” — the SFC interprets this as requiring sector-specific expertise, not generic financial due diligence.

Technology and Software: Intangible Assets and Recurring Revenue Verification

Technology companies, particularly those with software-as-a-service (SaaS) or platform-based business models, now represent 28.4% of the GEM and Main Board IPO pipeline as of 30 June 2025 (HKEX, Pipeline Statistics). The due diligence challenge here is twofold: the valuation of internally generated intangible assets, and the verification of recurring revenue metrics such as annual recurring revenue (ARR) and net dollar retention (NDR).

Intangible Asset Valuation Under HKFRS 3 and HKFRS 38

Technology applicants frequently capitalise development costs for proprietary software platforms, then carry these assets at cost less amortisation. The SFC’s 2024 review found that 11 of the 22 deficient cases (50%) involved technology companies where the sponsor had not verified the impairment testing methodology under HKFRS 36. Specifically, sponsors accepted management’s value-in-use calculations without independent verification of the discount rate, growth rate, or forecast period assumptions.

The sponsor’s due diligence must require the applicant to provide the complete impairment testing model for each material cash-generating unit (CGU). The sponsor should then engage an independent valuation specialist to opine on the discount rate (typically weighted average cost of capital, or WACC), the terminal growth rate, and the forecast period. The SFC expects the sponsor to document the basis for accepting management’s assumptions, including a sensitivity analysis showing the impact of a 100-basis-point change in the discount rate on the recoverable amount. Where the headroom (excess of recoverable amount over carrying value) is less than 20%, the sponsor should treat this as a heightened risk area requiring additional audit procedures.

Recurring Revenue Verification

SaaS and platform companies report ARR, NDR, and customer lifetime value (CLV) as key performance indicators (KPIs) in the listing document. The SFC’s 2024 review noted that sponsors in 7 cases accepted these metrics without verifying the underlying data from the applicant’s billing systems, customer contracts, or payment gateway records. The SFC’s Code of Conduct, paragraph 17.6(b), requires the sponsor to “verify the accuracy and completeness of information contained in the listing document” — this includes non-financial KPIs that are material to the investor’s understanding of the business.

The protocol: the sponsor’s due diligence team must perform a data extraction from the applicant’s customer relationship management (CRM) and billing systems, reconciling the contract start and end dates, contract values, and renewal terms to the reported ARR. A sample of at least 20% of the top 20 customers by revenue should be tested, with direct confirmation from the customer’s procurement department via written confirmation. The sponsor should also verify the calculation methodology for NDR: the SFC expects the sponsor to confirm that the denominator (beginning-period ARR) excludes customers who churned during the period, and that the numerator (ending-period ARR from the same cohort) includes upsells, cross-sells, and price increases. Any variance exceeding 5% between the sponsor’s recalculated metric and management’s reported figure requires a written explanation from the applicant’s CFO and, if material, an independent auditor’s review.

Financial Services: Regulatory Capital Adequacy and Counterparty Risk

Financial services applicants — including securities brokers, asset managers, and licensed money lenders — face the most stringent regulatory overlay of any sector in the Hong Kong IPO pipeline. The HKMA, SFC, and the Insurance Authority each impose specific capital adequacy and conduct requirements that the sponsor must verify as part of the suitability assessment under HKEX Listing Rule 9.03(3).

Regulatory Capital Compliance for Licensed Entities

For an applicant that holds an SFC Type 1 (dealing in securities) or Type 2 (dealing in futures contracts) licence, the sponsor must verify compliance with the Securities and Futures (Financial Resources) Rules (Cap. 571N, “FRR”). The FRR requires a licensed corporation to maintain liquid capital of at least HKD 3,000,000 for a Type 1 licence, and to calculate its adjusted liquid capital and total liabilities on a monthly basis (FRR, sections 4-12). The SFC’s 2024 review cited two cases where sponsors accepted the applicant’s FRR filings without independently verifying the calculation of the haircut applied to collateralised receivables.

The sponsor’s due diligence must include a review of the applicant’s FRR returns for the 24 months preceding the listing application, with a focus on the classification of assets as “liquid assets” under FRR Schedule 1. The sponsor should verify that the applicant has not classified unlisted equity investments or non-marketable securities as liquid assets, which would inflate the liquid capital position. For money lending applicants regulated under the Money Lenders Ordinance (Cap. 163), the sponsor must verify that the applicant holds a valid money lender’s licence and has not exceeded the maximum interest rate of 60% per annum under section 24 of the Ordinance. The HKEX’s Listing Decision LD127-2023 rejected a money lending applicant where the sponsor had not verified the interest rate compliance across the loan portfolio — the exchange found that 14% of the loans carried effective interest rates exceeding the statutory cap.

Counterparty Risk in Asset Management Applicants

For asset management applicants with material exposure to third-party funds or structured products, the sponsor must assess counterparty risk under the SFC’s Fund Manager Code of Conduct (FMCC), paragraph 4.1, which requires fund managers to “manage the risks associated with the use of financial derivative instruments and other leveraged instruments.” The SFC’s 2024 review identified that sponsors in 5 cases did not verify the applicant’s counterparty credit risk assessment methodology, particularly for over-the-counter (OTC) derivatives.

The sponsor should require the applicant to provide its counterparty risk policy, including the credit rating thresholds for approved counterparties (typically investment grade, or BBB- or higher by S&P or equivalent), the collateral management framework, and the stress-testing scenarios applied to the portfolio. The sponsor must then independently verify the counterparty exposure by obtaining confirmations from the applicant’s prime brokers or custodians, and reconcile these to the applicant’s internal risk reports. Where the applicant has exposure to a single counterparty exceeding 20% of net asset value (NAV), the sponsor should treat this as a material risk requiring disclosure in the risk factors section of the listing document and a written justification from the applicant’s board.

Cross-Sector Risks: Related Party Transactions and VIE Structures

Two risk categories cut across all sectors and have been the subject of multiple SFC enforcement actions and HKEX listing decisions: related party transactions (RPTs) under HKEX Listing Rules Chapter 14A, and variable interest entity (VIE) structures for PRC-based applicants.

Related Party Transactions Under Chapter 14A

The SFC’s 2024 review found that 15 of the 30 cases (50%) involved inadequate due diligence into RPTs. The most common failure: the sponsor accepted management’s characterisation of a transaction as “de minimis” without verifying that the transaction was conducted on normal commercial terms and at arm’s length, as required under Listing Rule 14A.90. The sponsor must obtain the applicant’s internal RPT register, then independently verify the pricing for each material RPT by comparing it to independent market quotations or third-party benchmark data. For transactions with a PRC-based related party, the sponsor should also verify the foreign exchange approval under the State Administration of Foreign Exchange (SAFE) regulations, as unapproved cross-border RPTs can render the transaction void under PRC law.

VIE Structure Verification for PRC Applicants

For PRC-based applicants using a VIE structure to circumvent foreign ownership restrictions in sectors such as education, internet content, or healthcare, the sponsor must verify the enforceability of the VIE agreements under PRC contract law. The HKEX’s Guidance Letter HKEX-GL94-18 (updated March 2024) requires the sponsor to obtain a PRC legal opinion confirming that the VIE agreements are valid, binding, and enforceable. The SFC’s 2024 review cited two cases where the sponsor accepted a PRC legal opinion that did not specifically address the risk of the VIE agreements being voided under the PRC Civil Code, Article 153, which renders contracts void if they violate mandatory legal provisions.

The sponsor’s due diligence must include a review of the PRC legal opinion against the specific regulatory restrictions applicable to the applicant’s industry, as set out in the PRC Foreign Investment Negative List (2024 edition). The sponsor should also verify that the VIE agreements have been registered with the local Administration for Market Regulation (AMR) where required, and that the nominee shareholders holding the PRC operating company’s equity have executed irrevocable powers of attorney in favour of the listed entity. Failure to do so was the basis for the HKEX’s rejection in LD140-2023, where the exchange found that the VIE structure was not legally enforceable because the nominee shareholders had not granted the power of attorney.

Actionable Takeaways for Sponsors

1. Implement a sector-specific due diligence checklist at the engagement acceptance stage, with mandatory verification steps for each of the three highest-risk sectors — healthcare, technology, and financial services — as identified by the SFC’s 2024 thematic review.

2. Engage an independent valuation specialist for every listing applicant with material internally generated intangible assets or goodwill, and document the basis for accepting management’s impairment testing assumptions with a sensitivity analysis showing a 100-basis-point change in the discount rate.

3. Perform a direct data extraction from the applicant’s billing or CRM systems for all revenue-based KPIs (ARR, NDR, customer retention), reconciling a minimum 20% sample of the top 20 customers to written confirmations from the customer’s procurement department.

4. Verify regulatory capital compliance for licensed financial services applicants by reviewing FRR returns for the preceding 24 months and reconciling the classification of liquid assets against FRR Schedule 1, with a specific check for unlisted equity misclassification.

5. Obtain a PRC legal opinion that explicitly addresses the enforceability of VIE agreements under the PRC Civil Code, Article 153, and the Foreign Investment Negative List (2024 edition), and verify that nominee shareholders have executed irrevocable powers of attorney.